Put companies on watchlist
Medacta Group SA
ISIN: CH0468525222
WKN: A2PFTD
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Medacta Group SA · ISIN: CH0468525222 · EQS - Company News (96 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1759675
30 October 2023 07:00AM

Medacta Announces the Launch of GMK SpheriKA, the World's First Knee Implant Optimized for Kinematic Alignment (KA)


Medacta Group SA / Key word(s): Product Launch/Product Launch
Medacta Announces the Launch of GMK SpheriKA, the World's First Knee Implant Optimized for Kinematic Alignment (KA)

30.10.2023 / 07:00 CET/CEST


MEDIA RELEASE

Medacta Announces the Launch of GMK SpheriKA, the World's First Knee Implant Optimized for Kinematic Alignment (KA)

Castel San Pietro, October 30, 2023 – Medacta Group S.A. ('Medacta,' SIX: MOVE), a Swiss company featuring innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgeries, is pleased to announce the launch of GMK SpheriKA, the world's first KA-optimized femoral component indicated for total knee replacement. GMK SpheriKA will make its worldwide debut on November 2 at the 2023 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting.

"GMK SpheriKA further reinforces Medacta's commitment to providing surgeons with personalized solutions for each of their patients," shared Francesco Siccardi, Chief Executive Officer of Medacta International."By working together with an international team of orthopaedic surgeon experts, we have introduced a product that builds upon our clinically proven GMK Sphere and incorporates the fundamentals of Kinematic Alignment to ensure that each patient receives an implant that can accommodate their unique anatomy."

Medacta's continuous commitment to positively impacting patients requiring a total knee procedure has evolved with the development of the concept of Kinematic Alignment, which restores the native pre-arthritic alignment through anatomic resurfacing, minimizing ligament releases, and allowing for a more natural knee kinematic. This approach has been shown to improve patient satisfaction compared to the more traditional techniques [1-3]. Over the past few years, clinical studies have highlighted that GMK Sphere is a particularly suitable implant for Kinematic Alignment, with the potential to further enhance patient outcomes compared to other knee designs [4-6].

Built upon the legacy of the GMK Sphere's ball-in-socket design, GMK SpheriKA offers patients an implant that potentially feels more natural and stable during daily activities, replicating the movement of the healthy knee.In addition,GMK SpheriKA features optimized femoral coverage and patellar tracking for Kinematic Alignment procedures, making it the first implant on the market specifically designed for this technique.

"I am thrilled to offer the GMK SpheriKA to my patients," said surgeon developer and Kinematic Alignment pioneer Stephen Howell, MD."The implant design provides a personalized option that addresses each patient's unique anatomy and patellofemoral kinematics, restoring a more normal feeling knee and a quick return of motion and daily activities."

MyKA, Medacta's Kinematic Alignment Platform, provides surgeons with the most comprehensive solution to safely and reproducibly perform Kinematic Alignment. In addition to GMK SpheriKA, it includes dedicated instrumentation and a tailored education program provided by the M.O.R.E. Institute, supported by an international network of expert surgeons. Moreover, the platform is enhanced by cutting-edge technologies, such as a dedicated planning protocol for the MyKnee 3D printed patient-matched guides and NextAR Knee, our Augmented Reality surgical application, which provides unique real-time data to efficiently complement the operative workflow. Both NextAR Knee and MyKnee are part of the MySolutions Personalized Ecosystem, Medacta's network of advanced digital solutions designed to improve patient outcomes and healthcare efficiency.

To learn more, please visit Medacta at AAHKS, Dallas (TX), November 2-5, 2023, at booth #1016, or register at spherika-aahks23.medacta.com to receive updates on GMK SpheriKA product developments, resources, and events.

REFERENCES
[1] Dosset et al. A randomised controlled trial of kinematically and mechanically aligned total knee replacements. Bone Joint J 2014; 96-B:907–13
[2] Lee et al. Early Outcomes of Kinematic Alignment in Primary Total Knee Arthroplasty: A Meta-Analysis of the Literature, The Journal of Arthroplasty 32 (2017) 2028-2032
[3] Yaron, Bar Ziv et al. “Patients undergoing staged bilateral knee arthroplasty are less aware of their kinematic aligned knee compared to their mechanical knee.” Journal of orthopaedics vol. 23 155-159. 20 Jan. 2021
[4] Scott, David F., and Celeste G. Gray. "Outcomes are better with a medial-stabilized vs a posterior-stabilized total knee implanted with kinematic alignment." The Journal of Arthroplasty 37.8 (2022): S852-S858
[5] Scott, David F., and Amy A. Hellie. "Mid-Flexion, Anteroposterior Stability of Total Knee Replacement Implanted with Kinematic Alignment: A Randomized, Quantitative Radiographic Laxity Study with Posterior-Stabilized and Medial-Stabilized Implants." JBJS 105.1 (2023): 9-19.
[6] JONES, Brett K.; CARLSON, Brian J.; SCOTT, David F. Better flexion and early recovery with medial-stabilized vs single-radius total knee arthroplasty with kinematic alignment: Two-year clinical results. The Knee, 2023, 43: 217-223
 

Contact
Medacta International SA
Gianluca Olgiati     
Senior Director Global Marketing  
Phone: +41 91 696 60 60
media@medacta.ch

ABOUT MEDACTA
Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon experts globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 50 countries. Follow us on Medacta TV, YouTube, LinkedIn, and Twitter.

RELATED TRADEMARKS
Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts. GMK® SpheriKA, GMK® Sphere, MyKA™, MyKnee®, MySolutions™ Personalized Ecosystem, NextAR™ Knee.

 


Additional features:

File: Medacta Announces the Launch of GMK SpheriKA, the World's First Knee Implant Optimized for Kinematic Alignment (KA)


End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1759675

 
End of News EQS News Service

1759675  30.10.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1759675&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Medacta Group SA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.